Industry & Business

€5 Billion Investment in Irish BioPharma Sector

 Breaking News
  • Grand Canal Innovation District Planned For Dublin A far-reaching plan for the creation of the Grand Canal Innovation District in Dublin has been launched. The proposal from Trinity College Dublin is modelled on innovation districts in cities such as Boston, Toronto, Rotterdam and Barcelona. It will significantly strengthen Ireland’s competitive advantage when developing new indigenous companies or competing for foreign direct investment. [...]...
  • Heiton Buckley Unveils Newly Refurbished Mayo Branch Heiton Buckley, Ireland’s leading supplier of doors, floors, bathrooms, garden, plumbing and heating products, has officially unveiled its newly refurbished branch in Castlebar, County Mayo . GAA star, Andy Moran, CEO of Grafton Merchanting ROI, Patrick Atkinson, Heiton Buckley Castlebar Branch Manager, Mick Kane, and longtime customer Mick Duane officially cut the ribbon and kicked [...]...
  • Export Sales by Enterprise Ireland Client Companies Hit New Record Enterprise Ireland, the state agency responsible for helping Irish companies export to international markets, has announced that its clients recorded export sales of €22.71 billion in 2017, representing a 7 per cent increase on 2016. This is the highest level of export sales recorded in the history of the agency and the eighth-consecutive year of [...]...
  • BAM Wins €25 Million Contract to Build New Cheese Factory in Cork TINE Ireland, a subsidiary of the Norwegian dairy co-operative TINE, has awarded the construction of a new Jarlsberg® cheese production facility and administration building at Mogeely, County Cork, to BAM Ireland. The contract value is more than €25 million. TINE is Norway’s largest producer, distributor and exporter of dairy products with 11,400 members (owners) and [...]...
  • HBAN Scoops Major European Business Angel Network Award HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland and InterTradeIreland, was crowned Globally Networked Organisation 2018 at the recent EBAN (European Business Angel Network) Awards Ceremony held in Sofia, Bulgaria. HBAN was awarded the prominent European accolade in recognition of the significant [...]...

€5 Billion Investment in Irish BioPharma Sector

€5 Billion Investment in Irish BioPharma Sector
February 03
12:18 2017

Capital investment projects valued at €5 billion have been recently completed or are currently in progress across the Irish biopharma industry, according to Matt Moran, Director of BioPharmachem Ireland, the Ibec association representing the biopharma, pharma and chemical sectors in Ireland. BioPharaChem Ireland’s primary aim is to ensure that Ireland remains a recognised global centre of excellence for innovation and development in pharmaceutical, biopharmaceutical and chemical supply.

“There has been a significant uplift in investment in Ireland,” Moran said. “It is looking positive at the moment for the country.” Generating over €60 billion worth of exports (about half of total country exports), the sector is a major contributor to the Irish economy.

“We are very much in expansionary mode,” Moran added.

However, to maintain this momentum, the Irish biopharma sector faces a number of key challenges, which were outlined by Moran in a keynote presentation at the recent National Manufacturing & Supply Chain Conference & Exhibition held at the Citywest Hotel, Dublin.

 He identified a number of key challenges facing the Irish biopharma sector if it is to maintain its current competitive advantages and continue in its role as a global centre of manufacturing, supply and development for the entire pharma sector – from small through medium to large molecule.

Ireland needs to ensure that it continues to create a competitive environment to promote growth, innovation and operational excellence. While it has a competitive rate of corporation tax, Ireland’s personal tax regime may prove problematic in attracting and retaining talented people within Irish industry. While Ireland’s talent pool remains a key global competitive advantage, it is essential to continue to ensure that highly trained people are available for the biopharma industry. Similarly, it is crucial that Ireland’s reputation as a global hub for innovation and manufacturing excellence is maintained.

Another key advantage enjoyed by the biopharma sector is the productive collaboration between industry, academia and government agencies. Over half of the Irish biopharma workforce has third level education. It is vital that this academic collaboration continues to consolidate Ireland’s position as a knowledge-based economy and as a primary location for R&D.

Continuity of investment in education is critical to ensuring that the necessary skills remain available to the industry. BioPharmachem Ireland advocates an increase in spending on science, technology and innovation to 2.5% of GDP by 2020.

“Ireland is recognised as a leading global location with regard to compliance with statutory and quality regulations,” Moran noted, indicating that this gives Irish companies a key competitive advantage over industries in other regions around the world. “The biopharma sector is very important for the country and it has the potential to grow further. It is important that we are not complacent. Our infrastructure needs to be state-of-the-art. Taxation, especially personal taxation, needs to be looked at.”

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4